Neuphoria Therapeutics Inc. NEUP
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 44.79% | -104.48% | 195.92% | -1,130.93% | -230.62% |
| Total Depreciation and Amortization | 0.06% | 0.18% | -0.18% | 0.06% | -0.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 65.59% | -221.02% | -297.56% | 275.28% | 226.00% |
| Change in Net Operating Assets | -86.70% | -240.58% | -962.00% | 216.54% | -25.89% |
| Cash from Operations | 133.86% | -129.13% | -91.65% | 14.40% | -19.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -50.96% | -- | 813,300.00% | -75.12% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 50.00% | -882.00% | -- | -- | -93.22% |
| Cash from Financing | -100.00% | -100.00% | 13,238.26% | 1,531.41% | -90.10% |
| Foreign Exchange rate Adjustments | -1,690.73% | 520.12% | 206.76% | -114.09% | -31.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 115.01% | -122.12% | 327.48% | 87.61% | -167.67% |